CA-ARKX-LABORATORIES
17.11.2020 07:02:08 CET | Business Wire | Press release
ArkX Laboratories , a leading provider of advanced far-field voice-capture technology, has appointed Redtree Solutions, the largest Pan-European electronic representative in the semiconductor industry, as the exclusive sales representative for its production-ready EveryWord™ voice solution in the Europe, Middle East and Africa (EMEA) marketplace.
This announcement coincides with growing demand from Fortune 1000 companies, OEMs, and start-ups in the region who want to bring their voice-enabled smart products and devices to market. The EveryWord™ portfolio offers a production-ready path that delivers an unmatched voice experience while mitigating risk, reducing development costs, and accelerating their time-to-market.
Featuring Cirrus Logic's SoundClear™ and FlexArray™ technologies, ArkX's advanced line of production-ready voice capture solutions outperform other existing solutions in far-field voice capture and deliver a far-superior voice experience to consumers. The products are Alexa-compatible and meet or exceed all requirements for the Amazon Voice Services (AVS) qualifications. In addition to Alexa, EveryWord™ is compatible with other platforms such as Google, Siri, Cortana, AliGenie, Baidu/Kitt.ai, Tencent, and Sensory. EveryWord™ voice solutions can be customized for a company's eco-system and applied to a wide range of products, including speakers, soundbars, televisions, appliances, voice controllers, and gadgets. For smart home applications, the modules can be installed in hubs, ceilings, and in-wall.
"The ArkX EveryWord portfolio solves the toughest problems facing innovative OEMs today, including capturing voice at a greater distance, around corners, in the presence of blaring TV, and other noisy and reverberative environments without having to lower playback volume," said ArkX CEO Eric Bauswell. "EveryWord truly outperforms the performance of standard far-field voice solutions by so large a margin that consumers will never want to go back to the 'old' technology."
Covering 19 countries with more than 500 active customers, Redtree will help accelerate ArkX Labs' market penetration in the region by generating greater awareness of the company's solutions and providing on-the-ground support to ArkX Labs' expanding customer base.
"We were impressed with the innovation and superior far-field performance of the EveryWord™ solutions. It's a huge leap forward and certainly the best far-field solutions ever seen on the marketplace over our 10+ years' experience in this segment," said Steve Judge, Redtree Solutions Managing Director. "The addition of ArkX's EveryWord™ voice solutions represent a strategic addition to our electronic component portfolio that will have appeal to many of our customers operating in the smart home, broadband telecom, consumer, robotic, automotive, and industrial marketplaces."
ArkX Executive Vice President Michael Lang added, "Redtree's experience, expertise, and support structure provides the perfect fit to help us expand our reach beyond existing North American and Asian markets."
The product line offers clear performance advantages for capturing voice commands from three times the standard distance, around corners, noisy and reflective environments, and without lowering playback volume. Additionally, EveryWord™ technology provides a unique ability to identify and to suppress speech from TV or other single-point noise sources.
EveryWord™ technology does not require source-ducking for reliable interaction, provides linear, circular, square, triangular, or 3D mic array geometries, and requires fewer microphones. The technology features ultra-low power battery operation for wake-on-word, and the flexibility for placement of microphones allows for in-wall, ceiling, or dashboard solutions. The 3D mic array versus other linear beam-forming approaches enables fewer blind spots and increased performance while incorporating fewer redundant microphone arrays for coverage.
About ArkX Laboratories
ArkX Laboratories, a joint venture between product development pioneer, Surfaceink, and consumer electronics manufacturer Ark Electronics USA brings an exceptional voice experience to the marketplace. Our next generation of advanced, high-performance far-field voice capture solutions, featuring Cirrus Logic and NXP technology, are Amazon pre-qualified and production-ready. ArkX provides Fortune 1000, OEMs, and start-ups who want their own branded, voice-enabled IoT products and smart devices with the ability to reduce their development time and costs and accelerate their time-to-market while mitigating the risk. For more information, please visit www.arkxlabs.com .
About Redtree Solutions
Redtree Solutions is the largest Pan-European Representative company in the region. More than 40 people provide service, speak local languages, and cover 19 countries with more than 500 active customers. Redtree invests in next-generation technologies for the benefit of its customers and is dedicated to their success. The Redtree application team is devoted to helping customers find the most optimized architecture for your Electronic systems, with the help of their partners' solutions and expertise. Redtree is headquartered near Oxford, UK. For more information, please visit www.redtree-solutions.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116006041/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom